The Short-Term Effects of Combined Modified Constraint-Induced Movement Therapy and Botulinum Toxin Injection for Children with Spastic Hemiplegic Cerebral Palsy

Abstract

Objective: The aim of this study was to investigate whether modified constraint-induced movement therapy (mCIMT) following a botulinum type A toxin (BoNT-A) injection enhances the effects of the BoNT-A injection into the spastic upper limb of children with hemiplegic cerebral palsy (CP).

Methods: A combined therapy with mCIMT and BoNT-A was given to 17 children in group A. Fifteen children in group B received only the BoNT-A injection. The muscle tone, the movement pattern, and the How Often and the How Well scales in the revised Pediatric Motor Activity Log (revised PMAL) were assessed before and 3 weeks after intervention.

Results: Three participants in group A dropped out due to poor tolerance of mCIMT. There were significant improvements in the muscle tone and the movement patterns for both groups (p<0.05), and the changes were not significantly different between the two groups. The How Often and the How Well scales in the revised PMAL were significantly improved in group A (p<0.05), but not in group B.

Conclusion: A combined therapy of mCIMT and BoNT-A seems to be helpful to enhance the effects of the BoNT-A injection in the functional use of the affected limb in children with hemiplegic CP.

Key words

cerebral palsy - hemiplegia - botulinum toxin - constraint-induced movement therapy - upper extremity

References

• 1 Baker R, Jasinski M, Maciag-Tymecka I. et al . Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.  Dev Med Child Neurol. 2002;  44 666-675
• 2 Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity.  Phys Ther. 1987;  67 206-207
• 3 Charles J, Lavinder G, Gordon AM. Effects of constraint-induced therapy on hand function in children with hemiplegic cerebral palsy.  Pediatr Phys Ther. 2001;  13 68-76
• 4 Charles JR, Wolf SL, Schneider JA. et al . Efficacy of a child-friendly form of constraint-induced movement therapy in hemiplegic cerebral palsy: a randomized control trial.  Dev Med Child Neurol. 2006;  48 635-642
• 5 Corry IS, Cosgrove AP, Duffy CM. et al . Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.  J Pediatr Orthop. 1998;  18 304-311
• 6 Corry IS, Cosgrove AP, Walsh EG. et al . Botulinum toxin A in the hemiplegic upper limb: a double-blind trial.  Dev Med Child Neurol. 1997;  39 185-193
• 7 Deluca SC, Echols K, Law CR. et al . Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial.  J Child Neurol. 2006;  21 931-938
• 8 DeLuca SC, Echols K, Ramey SL. et al . Pediatric constraint-induced movement therapy for a young child with cerebral palsy: two episodes of care.  Phys Ther. 2003;  83 1003-1013
• 9 Dettmers C, Teske U, Hamzei F. et al . Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke.  Arch Phys Med Rehabil. 2005;  86 204-209
• 10 Eliasson AC, Krumlinde-sundholm L, Shaw K. et al . Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model.  Dev Med Child Neurol. 2005;  47 266-275
• 11 Eliasson AC, Shaw K, Ponten E. et al . Feasibility of a day-camp model of modified constraint-induced movement therapy with and without botulinum toxin A injection for children with hemiplegia.  Phys Occup Ther Pediatr. 2009;  29 311-333
• 12 Glover JE, Mateer CA, Yoell C. et al . The effectiveness of constraint induced movement therapy in two young children with hemiplegia.  Pediatr Rehabil. 2002;  5 125-131
• 13 Gordon A, Connelly A, Neville B. et al . Modified constraint-induced movement therapy after childhood stroke.  Dev Med Child Neurol. 2007;  49 23-27
• 14 Gordon AM, Charles J, Wolf SL. Methods of constraint-induced movement therapy for children with hemiplegic cerebral palsy: development of a child-friendly intervention for improving upper-extremity function.  Arch Phys Med Rehabil. 2005;  86 837-844
• 15 Graham HK, Aoki KR, Autti-Ramo I. et al . Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.  Gait Posture. 2000;  11 67-79
• 16 Hoare B, Imms C, Carey L. et al . Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy: a Cochrane systematic review.  Clin Rehabil. 2007;  21 675-685
• 17 Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection.  Arch Phys Med Rehabil. 2003;  84 444-454
• 18 Hurvitz EA, Conti GE, Flansburg EL. et al . Motor control testing of upper limb function after botulinum toxin injection: a case study.  Arch Phys Med Rehabil. 2000;  81 1408-1415
• 19 Koman LA, Mooney 3rd JF, Smith BP. et al . Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.  J Pediatr Orthop. 1994;  14 299-303
• 20 Koman LA, Mooney 3rd JF, Smith BP. et al . Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.  J Pediatr Orthop. 2000;  20 108-115
• 21 Lennon S, Baxter D, Ashburn A. Physiotherapy based on the Bobath concept in stroke rehabilitation: a survey within the UK.  Disabil Rehabil. 2001;  23 254-262
• 22 Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy.  Dev Med Child Neurol. 2006;  48 170-175
• 23 Mackey AH, Walt SE, Lobb G. et al . Intraobserver reliability of the modified Tardieu scale in the upper limb of children with hemiplegia.  Dev Med Child Neurol. 2004;  46 267-272
• 24 Naylor CE, Bower E. Modified constraint-induced movement therapy for young children with hemiplegic cerebral palsy: a pilot study.  Dev Med Child Neurol. 2005;  47 365-369
• 25 Page SJ, Elovic E, Levine P. et al . Modified constraint-induced therapy and botulinum toxin A: a promising combination.  Am J Phys Med Rehabil. 2003;  82 76-80
• 26 Palisano R, Rosenbaum P, Walter S. et al . Development and reliability of a system to classify gross motor function in children with cerebral palsy.  Dev Med Child Neurol. 1997;  39 214-223
• 27 Park ES, Rha DW. Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review.  Yonsei Med J. 2006;  47 589-603
• 28 Pierce SR, Daly K, Gallagher KG. et al . Constraint-induced therapy for a child with hemiplegic cerebral palsy: a case report.  Arch Phys Med Rehabil. 2002;  83 1462-1463
• 29 Reeuwijk A, van Schie PE, Becher JG. et al . Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review.  Clin Rehabil. 2006;  20 375-387
• 30 Satila H, Kotamaki A, Koivikko M. et al . Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases.  Pediatr Rehabil. 2006;  9 247-258
• 31 Simpson DM, Gracies JM, Graham HK. et al . Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70 1691-1698
• 32 Speth LA, Leffers P, Janssen-Potten YJ. et al . Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy.  Dev Med Child Neurol. 2005;  47 468-473
• 33 Sterr A, Freivogel S. Intensive training in chronic upper limb hemiparesis does not increase spasticity or synergies.  Neurology. 2004;  63 2176-2177
• 34 Sterr A, Szameitat A, Shen S. et al . Application of the CIT concept in the clinical environment: hurdles, practicalities, and clinical benefits.  Cogn Behav Neurol. 2006;  19 48-54
• 35 Sun SF, Hsu CW, Hwang CW. et al . Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke.  Phys Ther. 2006;  86 1387-1397
• 36 Sun SF, Hsu CW, Sun HP. et al . Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study.  Neurorehabil Neural Repair. 2010;  24 34-41
• 37 Sung IY, Ryu JS, Pyun SB. et al . Efficacy of forced-use therapy in hemiplegic cerebral palsy.  Arch Phys Med Rehabil. 2005;  86 2195-2198
• 38 Sutcliffe TL, Gaetz WC, Logan WJ. et al . Cortical reorganization after modified constraint-induced movement therapy in pediatric hemiplegic cerebral palsy.  J Child Neurol. 2007;  22 1281-1287
• 39 Taub E, Ramey SL, DeLuca S. et al . Efficacy of constraint-induced movement therapy for children with cerebral palsy with asymmetric motor impairment.  Pediatrics. 2004;  113 305-312
• 40 Taub E, Uswatte G. Constraint-induced movement therapy: bridging from the primate laboratory to the stroke rehabilitation laboratory.  J Rehabil Med. 2003;  34-40
• 41 Wallen M, Bundy A, Pont K. et al . Psychometric properties of the pediatric motor activity log used for children with cerebral palsy.  Dev Med Child Neurol. 2009;  51 200-208
• 42 Wallen M, Bundy A, Pont K. et al . Psychometric properties of the pediatric motor activity log used for children with cerebral palsy.  Dev Med Child Neurol. 2008; 
• 43 Wallen MA, O’Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial.  Arch Phys Med Rehabil. 2004;  85 192-200
• 44 Willis JK, Morello A, Davie A. et al . Forced use treatment of childhood hemiparesis.  Pediatrics. 2002;  110 94-96
• 45 Yang TF, Fu CP, Kao NT. et al . Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.  Am J Phys Med Rehabil. 2003;  82 284-289

Correspondence